BridgeBio Pharma, Inc. (NASDAQ: BBIO) saw its shares plummet 14.06% on Tuesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company reported a wider-than-expected loss, overshadowing its revenue beat and causing investor concern.

For Q2 2025, BridgeBio reported a loss of $0.95 per share, significantly missing the analyst consensus estimate of $0.81 per share. This represents a 17.43% larger loss than expected and only a slight improvement from the $1.06 per share loss in the same quarter last year. The company's net loss attributable to common stockholders ballooned to $181.9 million, compared to $73.5 million in Q2 2024.

Despite the disappointing bottom line, BridgeBio's top-line performance showed promise. The company posted quarterly revenue of $110.6 million, beating analyst expectations of $100.4 million by 10.10%. This marks a substantial increase from the $2.17 million reported in the same period last year, driven largely by $71.5 million in U.S. Attruby net product revenue. However, investors seemed more concerned with the widening losses, as reflected in the sharp stock decline during regular trading hours and continuing in after-hours trading.